Puma Biotechnology | PBYI - Cost Of Sales


Puma Biotechnology reported $29.1M in Cost of Sales for its fiscal quarter ending in September of 2024.





Cost Of Sales Change Date
Agios Pharmaceuticals USD 1.32M 560K Mar/2026
Alnylam Pharmaceuticals USD 211.12M 56.6M Mar/2026
Amgen USD 1.6B 187M Mar/2026
Biogen USD 797.5M 302M Mar/2026
BioMarin Pharmaceutical USD 199.48M 37.93M Mar/2026
Daiichi Sankyo JPY 118.28B 37.7B Dec/2025
Esperion Therapeutics USD 27.85M 13.43M Dec/2025
Exelixis USD 19.95M 6.53M Mar/2026
Gilead Sciences USD 1.44B 174M Mar/2026
Glaxosmithkline GBP 1.88B 1.6B Mar/2026
Incyte USD 104.5M 16.68M Mar/2026
MacroGenics USD 9.53M 585K Mar/2026
Moderna USD 955M 503M Mar/2026
Novartis USD 3.46B 83M Mar/2026
Pfizer USD 4.59B 1.7B Mar/2026
PTC Therapeutics USD 39.61M 23.31M Mar/2026
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Regeneron Pharmaceuticals USD 669.4M 84.8M Mar/2026
Roche Holding CHF 8.48B 4.61B Dec/2025
Sangamo BioSciences 2.42M 1.11M Jun/2024
Sarepta Therapeutics USD 109.46M 289.93M Mar/2026
Takeda JPY 560.54B 159.39B Mar/2026
TG Therapeutics USD 33.51M 4.63M Mar/2026
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024
Vertex Pharmaceuticals USD 392.8M 73.2M Mar/2026